Filing Analysis
Compass Therapeutics, Inc. filed an 8-K to furnish its quarterly and semi-annual financial results for the period ending June 30, 2026. The filing serves as a formal announcement of earnings via a press release.
📋 Key Facts
- Report date: August 6, 2026
- Reporting period: Quarter and six months ended June 30, 2026
- The company furnished financial results through Exhibit 99.1 (Press Release)
Compass Therapeutics updated its corporate presentation to include recent clinical data from the COMPANION-002 study. This is a routine disclosure under Regulation FD.
📋 Key Facts
- Updated corporate presentation dated July 2026 furnished as Exhibit 99.1.
- Presentation includes data from the COMPANION-002 clinical study.
- Filing made pursuant to Item 7.01 (Regulation FD Disclosure).
Compass Therapeutics, Inc. filed an 8-K to furnish its quarterly and nine-month financial results for the period ended September 30, 2025.
📋 Key Facts
- Reporting date: November 5, 2025
- Period covered: Quarter and nine months ended September 30, 2025
- The filing serves to furnish financial results via a press release (Exhibit 99.1)
Compass Therapeutics announced a significant equity offering to raise approximately $112.5 million through the sale of common stock and pre-funded warrants at $3.00 per share. The proceeds are intended for commercial readiness, clinical development, and general corporate purposes.
🚩 Red Flags
- Significant dilution: Issuance of over 39 million total shares (including warrants/options) represents substantial equity dilution for existing shareholders.
📋 Key Facts
- Offering size: 33,290,000 firm shares at $3.00/share plus up to 6,710,000 pre-funded warrants at $2.9999/warrant.
- Underwriters include Jefferies LLC, Piper Sandler & Co., and Guggenheim Securities, LLC.
- Estimated net proceeds: ~$112.5 million (base) or ~$129.5 million if underwriters exercise the over-allotment option for 6,000,000 additional shares.
- Expected closing date: On or about August 14, 2025.
- Cash runway extension: Company expects proceeds to fund operations into 2028.
Compass Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter and six months ended June 30, 2025. The filing includes a press release, earnings call slides, and an updated corporate presentation.
📋 Key Facts
- Report date: August 11, 2025
- Reporting period: Quarter and six months ended June 30, 2025
- Company is an emerging growth company
- Included exhibits: Press release (99.1), Earnings call slides (99.2), and August 2025 corporate presentation (99.3)
Compass Therapeutics, Inc. held its Annual Meeting of Stockholders on June 11, 2025. The meeting resulted in the election of three directors and the ratification of CohnReznick, LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting of Stockholders held on June 11, 2025.
- Three Class II nominees elected to serve until the 2028 Annual Meeting: Carl L. Gordon, Philip J. Ferneau, and James P. Boylan.
- Stockholders ratified the appointment of CohnReznick, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Ratification of auditor received significant support with 114,283,119 votes 'For'.
Compass Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2025. The filing primarily serves as a vehicle to incorporate the company's press release into the SEC record.
📋 Key Facts
- Reporting date: May 8, 2025
- Period covered: Quarter ended March 31, 2025
- The filing contains results of operations and financial condition under Item 2.02
- Company is an emerging growth company
Compass Therapeutics announced positive top-line data from its Phase 2/3 COMPANION-002 study, where tovecimig in combination with paclitaxel met the primary efficacy endpoint for biliary tract cancer (BTC). The trial showed a statistically significant improvement in Overall Response Rate (ORR) compared to paclitaxel alone.
🚩 Red Flags
- Secondary endpoints (PFS, OS) are not yet mature, meaning long-term efficacy and survival benefits remain unproven.
📋 Key Facts
- Primary Endpoint: 17.1% ORR for tovecimig + paclitaxel vs. 5.3% for paclitaxel alone (p=0.031).
- Study Population: 168 total patients; 111 in the combination arm, 57 in the control arm.
- Secondary Endpoints: PFS, OS, and DoR data are not yet mature; expected in Q4 2025.
- Safety: Data Monitoring Committee (DMC) recommended continuation of the study without modification at four meetings.
- Timeline: Secondary endpoint analysis is anticipated to reach event thresholds in Q3 2025.
Compass Therapeutics, Inc. filed an 8-K to furnish its annual financial results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of the company's year-end earnings release.
📋 Key Facts
- Report date: February 27, 2025
- Reporting period: Year ended December 31, 2024
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an 'Emerging Growth Company'
Compass Therapeutics issued a corporate update announcing the advancement of a new drug candidate and provided preliminary cash position details. The company reported approximately $127 million in cash, cash equivalents, and marketable securities as of December 31, 2024.
🚩 Red Flags
- Cash position is preliminary and may differ materially from audited year-end statements.
📋 Key Facts
- Reported unaudited/preliminary cash, cash equivalents, and marketable securities of ~$127 million as of Dec 31, 2024.
- Announced advancement of a new drug candidate via press release (Exhibit 99.1).
- The reported cash position is subject to final financial closing procedures.
Compass Therapeutics, Inc. announced a leadership transition in its finance department, appointing Barry Shin as the new CFO and Neil Lerner as Principal Accounting Officer, effective December 9, 2024.
🚩 Red Flags
- The CEO (Thomas Schuetz) is stepping down from his role as 'principal financial officer', though he remains President and CEO according to the signature block.
- Rapid turnover or restructuring in finance leadership can sometimes precede reporting delays, though no restatements were mentioned here.
📋 Key Facts
- Barry Shin appointed Chief Financial Officer (CFO) on Dec 9, 2024, replacing Thomas Schuetz in that specific capacity.
- Shin's compensation includes a $475,000 base salary, 45% target bonus, and a $50,000 sign-on bonus.
- Equity grants to Shin include 400,000 stock options (strike price $1.65) and 400,000 Restricted Stock Units (RSUs).
- Neil Lerner, currently VP of Finance, appointed as Principal Accounting Officer.
- Shin previously served as COO/CFO at Trevena, Inc. and held roles at Mizuho Securities and Guggenheim Securities.
Compass Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2024.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing is a standard earnings release under Item 2.02.
Compass Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2024. The filing consists of a press release containing the company's recent financial performance and operational updates.
📋 Key Facts
- Report date: August 12, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing is a standard earnings release under Item 2.02 of Form 8-K.
- Company is an emerging growth company.
Compass Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 13, 2024. The meeting included the election of two directors and the ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting of Stockholders held on June 13, 2024.
- Ellen V. Chiniara was elected to serve as Director until the 2027 Annual Meeting.
- Mary Ann Gray was elected to serve as Director until the 2027 Annual Meeting.
- Stockholders ratified the appointment of CohnReznick, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Compass Therapeutics announced the immediate resignation of CEO and Board member Dr. Vered Bisker-Leib, effective May 28, 2024. Thomas Schuetz, MD, PhD, has been appointed as the new President and CEO.
🚩 Red Flags
- Sudden departure of both CEO and a key officer (Principal Financial/Accounting Officer).
- Significant severance package involving 18 months of salary and COBRA premiums.
- The new CEO is also assuming the roles of Principal Financial and Accounting Officer, consolidating high-level responsibilities.
📋 Key Facts
- CEO Vered Bisker-Leib resigned from all positions (CEO, Board) effective May 28, 2024.
- The company will pay Dr. Bisker-Leib 18 months of base salary plus up to 18 months of COBRA premiums under a Separation Agreement.
- Dr. Bisker-Leib entered into a 15-month Consulting Agreement at $45,000 annually.
- Thomas Schuetz, MD, PhD (formerly President of R&D) appointed as new CEO and Principal Financial/Accounting Officer.
- The Board of Directors was reduced to seven members following the resignation.
Compass Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2024. The filing serves as a formal announcement of the company's recent earnings release.
📋 Key Facts
- Report date: May 13, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes Exhibit 99.1 containing the press release with financial results.
Compass Therapeutics announced that the FDA has granted Fast Track Designation for its lead asset, CTX-009 (in combination with paclitaxel), for the treatment of biliary tract cancer. This is a regulatory milestone intended to expedite the development and review process.
📋 Key Facts
- FDA granted Fast Track Designation for CTX-009 + paclitaxel.
- Target indication: Biliary tract cancer.
- Asset type: Investigational bispecific antibody (CTX-009).
- Filing date: April 25, 2024.
Compass Therapeutics, Inc. filed an 8-K to furnish its annual financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of the company's year-end earnings press release.
📋 Key Facts
- Report date: March 21, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes a press release as Exhibit 99.1 containing financial results.
- Company is an emerging growth company.
Compass Therapeutics announced a leadership succession plan involving the appointment of Dr. Vered Bisker-Leib as CEO and the transition of founder/CEO Thomas Schuetz to President of R&D and Vice Chair of the Board. The filing also includes updated employment agreements for both executives, including significant equity grants.
🚩 Red Flags
- Significant equity grants to both outgoing and incoming executives during a leadership transition can lead to dilution.
📋 Key Facts
- Dr. Vered Bisker-Leib appointed CEO and Board member effective January 9, 2024; base salary increased to $600,000 with a 55% target bonus.
- Dr. Schuetz transitions from CEO to President of R&D and Vice Chair of the Board, effective January 9, 2024.
- Dr. Bisker-Leib granted 1,753,125 stock options (strike price $1.93) and 1,753,125 RSUs.
- Dr. Schuetz granted 637,500 stock options (strike price $1.93) and 637,500 RSUs.
- Company reported approximately $152 million in cash, cash equivalents, and marketable securities as of December 31, 2023 (unaudited).
Compass Therapeutics provided a corporate update including an unaudited year-end cash position and announced changes in management and updated program timelines. The company reports approximately $152 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
🚩 Red Flags
- Management changes (often associated with strategic shifts or internal instability, though not inherently negative).
- Preliminary/unaudited nature of the reported $152M cash position may lead to material adjustments.
📋 Key Facts
- Estimated cash, cash equivalents, and marketable securities: ~$152 million as of Dec 31, 2023 (unaudited).
- The company issued a press release regarding updated program timelines and additional clinical data.
- Management changes were announced in conjunction with the corporate update.
- The cash position figure is preliminary and subject to change upon completion of financial closing procedures.